Bio
Dr. Warren Kruger graduated magna cum laude from Cornell, received his Ph.D in Biochemistry from the University of California, and was a Postdoctoral Fellow in the Department of Genetics at Stanford University. He is currently a full professor in the Cancer Biology program at Fox Chase Cancer Center, where he has been since 1995. His lab focuses on the study of sulfur amino acid metabolism and its relationship to human health and disease. He has worked on CBS deficiency since 1992, where he showed that human CBS could functionally substitute for the yeast enzyme. A key discovery made to Dr. Kruger was the finding that most patient-derived mutant CBS proteins have “cryptic” enzyme activity which can be uncovered by various genetic and pharmacologic manipulations. Also, Dr. Kruger’s lab has created several different mouse models of CBS deficiency that are used widely in the field. He has published more than 80 peer reviewed papers, been an invited speaker at numerous international conferences, and has obtained research grants from a wide variety of sources, including the National Institutes of Health, Department of Defense, American Cancer Society, and American Heart Association.
"What is: ERT, Chaperone Therapy, Gene editing, Gene Therapy"
The treatment landscape for Homocystinuria (HCU) is undergoing a historic shift beyond traditional dietary management. In this comprehensive session, Dr. Warren Kruger, from Fox Chase Cancer Center, will demystify the complex science behind emerging therapeutic approaches. This talk is designed to provide patients and caregivers with a clear "roadmap" of how these different technologies work to lower homocysteine and improve quality of life.